Viking Therapeutics (VKTX) Interest & Investment Income (2015 - 2026)
Viking Therapeutics (VKTX) reported Interest & Investment Income of -$1.2 million for Q1 2026, down 322.02% on a YoY basis from $563000.0 in Q1 2025, and down 12400.0% sequentially from -$10000.0 in Q4 2025.
Viking Therapeutics (VKTX) Interest & Investment Income (2015 - 2026) Analysis & Trends
Viking Therapeutics (VKTX) has 12 years of Interest & Investment Income data on file, last reported at -$1.2 million in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income fell 322.02% year-over-year to -$1.2 million; the trailing twelve-month figure through Mar 2026 stood at -$694000.0 (down 145.84% YoY), and the FY2025 full-year result was $1.1 million, up 746.82% from the prior year.
- Interest & Investment Income retreated to -$1.2 million in Q1 2026, from -$10000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $3.9 million in Q3 2024 to a low of -$2.3 million in Q4 2024.
- A 5-year average of $8352.9 and a median of $26000.0 in 2025 frame the typical range for Interest & Investment Income.
- Across the five-year window, Interest & Investment Income sank 1686.0% in 2022 and soared 1665.61% in 2024, its largest moves.
- Tracing VKTX's Interest & Investment Income over 5 years: stood at $518000.0 in 2022, then declined by 15.64% to $437000.0 in 2023, then plunged by 615.33% to -$2.3 million in 2024, then surged by 99.56% to -$10000.0 in 2025, then plunged by 12400.0% to -$1.2 million in 2026.
- Business Quant data shows VKTX's Interest & Investment Income at -$1.2 million in Q1 2026, -$10000.0 in Q4 2025, and $540000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | Viking Therapeutics | 4.09 Bn | 4.09 Bn | - | -1.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.25 Mn |
| Dec 31, 2025 | -10,000.00 |
| Sep 30, 2025 | 540,000.00 |
| Jun 30, 2025 | 26,000.00 |
| Mar 31, 2025 | 563,000.00 |
| Dec 31, 2024 | -2.25 Mn |
| Sep 30, 2024 | 3.90 Mn |
| Jun 30, 2024 | -699,000.00 |
| Mar 31, 2024 | -1.13 Mn |
| Dec 31, 2023 | 437,000.00 |
| Sep 30, 2023 | 221,000.00 |
| Jun 30, 2023 | -417,000.00 |
| Mar 31, 2023 | 501,000.00 |
| Dec 31, 2022 | 518,000.00 |
| Sep 30, 2022 | 111,000.00 |
| Jun 30, 2022 | -31,000.00 |
| Mar 31, 2022 | -893,000.00 |
| Dec 31, 2021 | -379,000.00 |
| Sep 30, 2021 | 19,000.00 |
| Jun 30, 2021 | -85,000.00 |